Real-time data provided for free by IEX. Vote “Underperform” if you believe ADMP will underperform the S&P 500 over the long term. This price target is based on 3 analysts offering 12 month price targets for Adamis Pharmaceuticals in the last 3 months. © American Consumer News, LLC dba MarketBeat® 2010-2021. Get daily stock ideas top-performing Wall Street analysts. Who this matters to: Overall Ranking is a comprehensive evaluation. The official website for Adamis Pharmaceuticals is www.adamispharmaceuticals.com. ADMP Stock Trend Given the current short-term trend, the stock is expected to rise 119.49% during the next 3 months and, with a 90% probability hold a price between $2.46 and $5.00 at the end of this 3-month period. Next reporting date: April 1, 2021: EPS forecast (this quarter)-$0.06: Annual revenue (last year) $22.1M: Annual profit (last year)-$29.3M: Net profit margin Fundamental company data provided by Zacks Investment Research. ET) and the After Hours Market (4:00-8:00 p.m. ADMP … This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adamis Pharmaceuticals in the last year. The specialty pharmaceutical company earned $4.30 million during the quarter, compared to the consensus estimate of $8.15 million. Adamis Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMP.". Vote “Outperform” if you believe ADMP will outperform the S&P 500 over the long term. By using the site you agree and are held ADMP stock was sold by a variety of institutional investors in the last quarter, including Verdence Capital Advisors LLC. The specialty pharmaceutical company earns $-29,310,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis. As of February 12th, there was short interest totaling 4,130,000 shares, a drop of 18.5% from the January 28th total of 5,070,000 shares. Users should not base their investment decision upon "StockInvest.us". ADMP Stock Forecast - Get a free ADMP stock predictions and find out whether you should buy or sell ADMP stock. ADMP | Complete Adamis Pharmaceuticals Corp. stock news by MarketWatch. Compare Top Brokerages Here. View real-time stock prices and stock quotes for a full financial overview. ET). Since then, ADMP shares have increased by 150.7% and is now trading at $1.01. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. WARNING: Trend forecast is still in the development phase and should be used with caution. Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ADMP … investment rating. Based on an average trading volume of 18,730,000 shares, the days-to-cover ratio is currently 0.2 days. On average, they expect … Price Action: ADMP stock is down 7.01% at $1.46 in market trading hours on last check Wednesday. Adamis Pharmaceuticals' management team includes the following people: World's 2nd Richest Man Is About To Shock The World. View institutional ownership trends for Adamis Pharmaceuticals. Adamis Pharmaceuticals is headquartered at 11682 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. There are currently 3 hold ratings for the stock. Learn everything you need to know about successful options trading with this three-part video course. report type. According to analysts' consensus price target of $1.25, Adamis Pharmaceuticals has a forecasted upside of 25.0% from its current price of $1.00. Maxim Group is very positive to ADMP and gave it a "Buy" rating on September 23, 2020. It's so revolutionary; it could even put an extra $30,000 in Americans' pockets. The analysis is useful for short term traders who trade stocks with technical anlaysis. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) trade information. Adamis Pharmaceuticals had a negative trailing twelve-month return on equity of 99.57% and a negative net margin of 188.31%. Adamis Pharmaceuticals has a market capitalization of $135.54 million and generates $22.11 million in revenue each year. What price target have analysts set for ADMP? On the other hand, Adamis Pharmaceuticl's target price … Elon Musk changed online payment processing with Paypal. Price is a widely used stock evaluation measure. The last closing price of the ADAMIS PHARMACEUTICALS CORP share was $0.51 and has changed by -0.76% since the penultimate trading day. And now, Elon Musk is getting ready to unveil his next big project: S.A.V. 1.2600 +0.0200 … Sr. Director of Investor Relations & Corp. Communications, Start Your Risk-Free Trial Subscription Here, Great Time to Buy Goodyear Tires (NYSE: GT) Stock Here, Here’s Where the S&P 500 (NYSEARCA: SPY) Can Go From Here, Xpeng, Inc (NYSE:XPEV) Is Loaded For Growth, Cloudera Is Flashing Some Good Buy Signals Before Earnings, Del Taco Restaurants Serves Up Combo Platter of Reasons to Buy In, Green Power Motor Stock Is A Perfect Play On EV, The Market Has Dick’s Sporting Goods (NYSE:DKS) By The Shorts, 7 Internet of Things Stocks That Are a Perfect Fit to Our Connected Future, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, Adamis gets FDA greenlight for tempol human studies in COVID-19, Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19, Adamis Pharmaceuticals Says Received Notice That One Patent Application Relating To ZIMHI Was Allowed By U.S. Patent And Trademark Office, Adamis Pharma Shares Fall Despite US Patent Covering Naloxone, Adamis Pharmaceuticals Strengthens Patent Portfolio for Its Naloxone Product Candidate, Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock, Adamis Pharmaceuticals and Human Immune Monitoring Center at Stanford University Announce Preliminary Tempol Data in Cells from COVID-19 Patients, Adamis Pharmaceuticals Provides Update On Its US Compounding Business, Adamis’ COVID-19 Treatment Has Potential, but the Stock Is Still Not a Buy: Analyst, Adamis (ADMP) Submits Tempol IND for COVID-19, Shares Soar, SYMJEPI Products Now Available in the Walgreens Prescription Savings Club, with the Lowest Prices for Epinephrine Products, Adamis Pharmaceuticals Announces IND Submission to FDA for Tempol for the Treatment of COVID-19, Adamis Soars After Submitting Covid Drug to FDA, Adamis Pharmaceuticals (ADMP) Surges: Stock Moves 6.7% Higher, Adamis Pharmaceuticals Describes Planned Response to ZIMHI Complete Response Letter, ADMP Snubbed Again, FDA Delay's Decision On BMY's Liso-cel, MRNA's COVID-19 Vaccine 94.5% Effective, Why Adamis Pharmaceuticals Stock Is Trading Lower Today, Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily.